Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $33.76 which represents a decrease of $-1.01 or -2.90% from the prior close of $34.77. The stock opened at $34.75 and touched a low of $33.34 ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...

In a report released today, Terence Flynn from Morgan Stanley assigned a Hold rating on Moderna (MRNA – Research Report), with a price target ...

The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Moderna stock slid nearly 17% on Monday, after the US biotech firm slashed its 2025 sales forecast range by $1bn. An ...

This innovative FTSE 250 stock has had a solid start to the year, rising 15% in just two days. Is it time I considered adding ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its ...